PRTG_OUT_1 [2025-03-27 16:40:31 -0400] 2402 Bytes | 684 tokens | Cum: 684 tkns (8.55% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Portage Biotech (PRTG) hit my radar screen, up to 6.2001 from a prev close of 4.54 Do you think its got more juice or is it lacking potential? It's 4:40:30 PM on Thu Mar 27, 2025 -0400 and I have to decide: buy or sell!

Here's the first list of news for Portage Biotech:

C1 - Today 04:15PM - Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
C2 - Mar-12-25 08:00AM - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
C3 - Feb-12-25 04:15PM - Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
C4 - Jan-30-25 04:30PM - Portage Biotech Announces Completion of $2.15 Million Private Financing
C5 - Jan-06-25 05:00AM - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
C6 - Dec-17-24 07:00AM - Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
C7 - Dec-12-24 04:15PM - Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
C8 - Nov-26-24 04:05PM - Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Prior AI Reports for PRTG:

1. 2025-03-24 – Score: 30 – Target: 4.9500 – Highs: 4.8000 / 4.4616 / 4.69
portage-biotech-high-insider-ownership-amid-negative-market-trends

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Portage Biotech (PRTG)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PRTG_OUT_3 [2025-03-27 16:40:34 -0400] 1098 Bytes | 341 tokens | Cum: 1027 tkns (12.84% of 8k)
==========================================================================

Showing C1 (chunk 1 of 5): C1:
**Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7**
Date: Today 04:15PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/27/3051025/0/en/Portage-Biotech-Reports-Promising-Preclinical-Results-in-Mesothelioma-Supporting-First-In-Human-Trial-of-PORT-7.html

March 27, 2025 16:15 ET| Source:Portage Biotech Inc.Portage Biotech Inc.

DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer Congress (ELCC), held in Paris, France March 26-29. The new data demonstrate both sing

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PRTG_OUT_5 [2025-03-27 16:40:35 -0400] 996 Bytes | 286 tokens | Cum: 1315 tkns (16.44% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T20:15:00Z - Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Tria...
A2 - 2025-03-12T19:23:00Z - Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6...
A3 - 2025-03-12T15:54:00Z - Portage Advances PORT-6 Clinical Trial With Encouraging Safety Data, Resumes Enrollment...
A4 - 2025-03-12T15:06:27Z - Portage resumes enrollment in final cohort of dose escalation for ADPORT-601...
A5 - 2025-03-12T12:23:55Z - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PRTG_OUT_7 [2025-03-27 16:40:37 -0400] 1098 Bytes | 330 tokens | Cum: 1647 tkns (20.59% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - Portage Biotech (NASDAQ:PRTG)**Date: 2025-03-27Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/03/g44524033/portage-biotech-reports-promising-preclinical-results-in-mesothelioma-supporting-first-in-human-trDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. PRTG, a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer Congress (ELCC), held in Paris, France March 26-29. The new data demonstrate both single agent activity for PORT-7, and a dramati

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PRTG_OUT_9 [2025-03-27 16:40:43 -0400] 1098 Bytes | 270 tokens | Cum: 1919 tkns (23.99% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): c >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. Immunohistochemistry of the tumors revealed a significant infiltration of both CD3 and CD45 positive immune effector cells. Mesothelioma is an aggressive cancer with limited treatment options in need of novel approaches to overcome immune resistance. To our knowledge, this is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage is making preparations to commence a first-in-human clinical trial with PORT-7.

Combining PORT-6 and PORT-7 for a More Comprehensive Immunotherapy Approach

In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor. Portage's plan is to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial. This wil

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PRTG_OUT_11 [2025-03-27 16:40:49 -0400] 1098 Bytes | 244 tokens | Cum: 2285 tkns (28.56% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): l mark the first time two highly selective A2A and A2B antagonists are combined in patients, with the aim of achieving a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment. This innovative approach is designed to fully neutralize adenosine-mediated immune suppression, enhance anti-tumor responses, and broaden the impact of immunotherapy in solid tumors.

About Portage Biotech

Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system's ability to fight cancer. For more information, visit www.portagebiotech.com.

All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company's business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or tha

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PRTG_OUT_13 [2025-03-27 16:40:54 -0400] 1098 Bytes | 271 tokens | Cum: 2667 tkns (33.34% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): t otherwise include the words "believe," "expects," "anticipates," "intends," "estimates," "will," "may," "plans," "potential," "continues," or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company's ability to continue as a going concern, scientific results may not be as expected, and other factors set forth in "Item 3 - Key Information-Risk Factors" in the Company's Annual Report on Form 20-F for the year ended March 31, 2024 and "Business Environment - Risk Factors" in the Company's Management's Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company's Form 6-K. Although the Company believes that

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PRTG_OUT_15 [2025-03-27 16:40:56 -0400] 1053 Bytes | 322 tokens | Cum: 3074 tkns (38.42% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-12T12:00:00Z - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
B2 - 2025-01-06T10:00:00Z - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
B3 - 2024-07-22T09:24:37Z - Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket - Benzinga
B4 - 2024-04-17T17:36:19Z - Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B5 - 2024-04-12T12:01:00Z - Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
B6 - 2024-03-26T12:01:00Z - Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRTG_OUT_17 [2025-03-27 16:41:02 -0400] 873 Bytes | 249 tokens | Cum: 3325 tkns (41.56% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/12/3041325/0/en/Portage-Biotech-Resumes-Enrollment-in-Final-Cohort-of-Dose-Escalation-for-Port-6-in-ADPORT-601-Trial.htmlPortage Biotech announced the resumption of patient enrollment in the final cohort of the dose escalation stage for its selective A2A antagonist, PORT-6, within its ADPORT-601 Phase 1b clinical trial. The company is also preparing to evaluate the continuation of the study into its potent and selective A2B antagonist, PORT-7, and combination arms.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PRTG_OUT_19 [2025-03-27 16:41:03 -0400] 238 Bytes | 59 tokens | Cum: 3476 tkns (43.45% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRTG_OUT_21 [2025-03-27 16:41:15 -0400] 3241 Bytes | 829 tokens | Cum: 4308 tkns (53.85% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+----------------------+
| Volume: 59,708 | Perf Month: 4.67% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 64.35K | Perf Quarter: -12.62% | Short Float: 8.64% | ROE: -194.84% |
+--------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.93 | Index: - | Short Ratio: 0.21 | ROI: -4812.45% |
+--------------------+-----------------------+------------------------+----------------------+
| RSI (14): 58.31 | Market Cap: 5.28M | Short Interest: 0.01M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.40 | Shs Outstand: 1.12M | Beta: 1.53 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA20: 10.44% | Shs Float: 0.16M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA50: 7.20% | Inst Own: 6.94% | Sales past 5Y: 0.00% | Earnings: Nov 26 AMC |
+--------------------+-----------------------+------------------------+----------------------+
| SMA200: 0.95% | Insider Own: 75.46% | Employees: 7 | |
+--------------------+-----------------------+------------------------+----------------------+
| Perf Week: 8.28% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+--------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.71
Average Volume: 22081.3
30-Day High: 4.71
30-Day Low: 4
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PRTG_OUT_23 [2025-03-27 16:41:18 -0400] 676 Bytes | 167 tokens | Cum: 4701 tkns (58.76% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PRTG_IN_25 [2025-03-27 16:41:19 -0400] 126 Bytes | 29 tokens | Cum: 4758 tkns (59.48% of 8k)
==========================================================================

====================================
[2025-03-27 13:41:19] # Analysis Completed
Elapsed Time: 49.42 seconds